Replimune’s oncolytic viral therapy Tudriqev (Tudriqev) won FDA accelerated approval for advanced melanoma, following a fast, high-stakes regulatory turnaround after the program was previously twice rejected. The approval positions the treatment as a more convenient option relative to cell therapy approaches used in the setting. The FDA’s decision came after a sequence of events that included an advisory committee vote and a resubmission cycle completed in less than four months, according to the reporting. Replimune will now operate under the accelerated approval framework while continuing to generate additional evidence in ongoing studies. For developers of next-generation immuno-oncology modalities, the message is clear: the FDA remains willing to reconsider oncolytic approaches when the evidence package aligns with unmet needs and benefit/risk profiles in late-stage disease.